Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab together with combination chemotherapy may kill more cancer cells.

PURPOSE: This clinical trial is studying the side effects and best ways to give combination chemotherapy together with rituximab in treating patients with newly diagnosed primary CNS lymphoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: National Cancer Institute (NCI)
• Treatments: Calcium, Dietary; Cytarabine; Etoposide; Etoposide phosphate; Leucovorin; Levoleucovorin; Methotrexate; Rituximab; Temozolomide

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed untreated primary CNS lymphoma (PCNSL) confirmed by 1 of the following methods:

• Brain biopsy or resection

• Patients diagnosed with T-cell PCNSL allowed but will not receive rituximab on study

• Cerebrospinal fluid (CSF) cytology

• Positive CSF cytology with or without measurable intracranial disease

• Vitreal biopsy

• Histologic confirmation of vitreal lymphoma with measurable intracranial tumor

• No evidence of systemic non-Hodgkin's lymphoma

• CT scan of chest, abdomen, and pelvis or bone marrow biopsy negative for extracerebral source of lymphoma

• No evidence of pleural effusions or ascites

• MRI of brain and spine (plus gadolinium) must have measurable contrast enhancing disease unless CSF cytology is positive

PATIENT CHARACTERISTICS:

• Karnofsky performance score 50-100%

• HIV negative

• Creatinine clearance ≥ 50 mL/min

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• No concurrent salicylates, nonsteroidal anti-inflammatory drugs, sulfonamides, or penicillins within the past week